IDH2 and glioblastoma: Promoter meythlation of the O6-methylguanine-DNA methyltransferase (MGMT) and IDH1/IDH2 has a particularly high prevalence in LGG (44), and methylation of the MGMT promoter is predictive for treatment response in glioblastoma patients (45).